<DOC>
	<DOC>NCT01118572</DOC>
	<brief_summary>Aim of the study is to compare efficacy and safety of YM177 with placebo and etodolac in patients with postoperative pain.</brief_summary>
	<brief_title>A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients</brief_title>
	<detailed_description>To verify the superiority to placebo and the noninferiority to etodolac of YM177 in terms of efficacy assessment in patients with postoperative pain. Also, to compare them in terms of safety assessment.</detailed_description>
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Etodolac</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Patients with spontaneous pain within 24 hours postoperatively The intensity of the pain: 4categorical assessment: "Moderate pain" or "Severe pain" VAS assessment: 45.0 mm or higher Patients whose postoperative pain can be managed using an oral NSAID A past history of aspirininduced asthma A past of ischemic heart disease, serious arrhythmia, congestive heart failure or cerebrovascular disease Patients who undergoes the surgical procedure under general anesthesia Patients taking excluded medications</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Celecoxib</keyword>
	<keyword>Celecox</keyword>
	<keyword>Pain</keyword>
	<keyword>Surgery</keyword>
	<keyword>NSAIDs</keyword>
</DOC>